Understand the source comparison
LL-37 Wound Healing Results Timeline Expect: Peptide vs Growth Factor Comparison
Researchers often compare LL-37 to established wound healing agents like platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). The mechanisms and timelines differ meaningfully. LL-37 (10–50 µg/mL) Direct anti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers often compare LL-37 to established wound healing agents like platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). The mechanisms and timelines differ meaningfully.
- LL-37 (10–50 µg/mL)
- Direct antimicrobial activity + neutrophil chemotaxis + EGFR activation
- Antimicrobial: 6–24 hrs / Structural: 3–7 days
- Reduces CFUs 80–95% within 24 hrs
- 30–50% faster (days 3–7)
- Strong (via FPRL1 and P2X7)
- PDGF (10–100 ng/mL)
- Fibroblast and smooth muscle proliferation
- 5–10 days (structural only)
- None. Requires clean wound bed
- 15–25% faster (days 7–14)
- Moderate (indirect via fibroblast recruitment)
- EGF (5–50 ng/mL)
- Keratinocyte proliferation via EGFR
- 3–7 days
- None
- 20–35% faster (days 5–10)
- Weak
- FGF-2 (1–10 ng/mL)
- Endothelial cell and fibroblast mitogenesis
- 7–14 days
- 10–20% faster (days 10–14)
- Very strong (primary mechanism)
- Untreated Control
- Endogenous healing cascade
- 10–14 days baseline
- Baseline infection persists
- Baseline
- Bottom Line / Professional Assessment
- LL-37 is the only agent with direct antimicrobial activity. It works in infected wounds where growth factors fail. Faster early-phase results, but growth factors may outperform in sterile, vascularized wounds.
- PDGF and FGF excel in clean chronic wounds. EGF overlaps LL-37's keratinocyte pathway but lacks antimicrobial function. LL-37 is superior in diabetic ulcers and infected wounds.
- LL-37 reduces infection first, then accelerates closure. Growth factors require infection control before application.
- LL-37 shows fastest early closure (days 3–7). PDGF shows sustained late closure (days 10–14).
- FGF-2 strongest for angiogenesis alone. LL-37 combines moderate angiogenesis with antimicrobial and immune effects.
- The critical distinction: LL-37 doesn't require a sterile wound bed to function. Growth factors applied to infected or biofilm-colonized wounds show minimal efficacy because bacterial proteases degrade the peptide before it can act. LL-37 clears the infection while simultaneously stimulating healing. Making it uniquely effective in chronic diabetic ulcers and pressure sores where infection is nearly universal.